These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37556092)

  • 21. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.
    Zeh HJ; Downs-Canner S; McCart JA; Guo ZS; Rao UN; Ramalingam L; Thorne SH; Jones HL; Kalinski P; Wieckowski E; O'Malley ME; Daneshmand M; Hu K; Bell JC; Hwang TH; Moon A; Breitbach CJ; Kirn DH; Bartlett DL
    Mol Ther; 2015 Jan; 23(1):202-14. PubMed ID: 25292189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An evaluation of talimogene laherparepvec for the treatment of melanoma.
    Broman KK; Zager JS
    Expert Opin Biol Ther; 2020 Jan; 20(1):9-14. PubMed ID: 31690129
    [No Abstract]   [Full Text] [Related]  

  • 23. Injectable Therapies for Regional Melanoma.
    Farrow NE; Leddy M; Landa K; Beasley GM
    Surg Oncol Clin N Am; 2020 Jul; 29(3):433-444. PubMed ID: 32482318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
    Kohlhapp FJ; Zloza A; Kaufman HL
    Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of Locoregionally Advanced Melanoma.
    Pointer DT; Zager JS
    Surg Clin North Am; 2020 Feb; 100(1):109-125. PubMed ID: 31753106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.
    Hamid O; Hoffner B; Gasal E; Hong J; Carvajal RD
    Cancer Immunol Immunother; 2017 Oct; 66(10):1249-1264. PubMed ID: 28712033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncolytic virus immunotherapy for melanoma.
    Dharmadhikari N; Mehnert JM; Kaufman HL
    Curr Treat Options Oncol; 2015 Mar; 16(3):326. PubMed ID: 25777572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
    Garnock-Jones KP
    BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Developments in Intralesional Therapy for Metastatic Melanoma.
    Sloot S; Rashid OM; Sarnaik AA; Zager JS
    Cancer Control; 2016 Jan; 23(1):12-20. PubMed ID: 27009452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18.
    Au GG; Beagley LG; Haley ES; Barry RD; Shafren DR
    Virol J; 2011 Jan; 8():22. PubMed ID: 21241513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Talimogene Laherparepvec for the Treatment of Advanced Melanoma.
    Ott PA; Hodi FS
    Clin Cancer Res; 2016 Jul; 22(13):3127-31. PubMed ID: 27146699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NICE guidance for talimogene laherparepvec for unresectable metastatic melanoma.
    Adam J; Robertson J; Donegan E; Voicechovskaja I
    Lancet Oncol; 2016 Nov; 17(11):1485-1486. PubMed ID: 27692478
    [No Abstract]   [Full Text] [Related]  

  • 33. Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab.
    Naqash AR; Stroud G; Collichio FA; Muzaffar M; Sharma N; Walker P
    Acta Oncol; 2017 Oct; 56(10):1327-1330. PubMed ID: 28481677
    [No Abstract]   [Full Text] [Related]  

  • 34. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The Advances of Oncolytic Herpes Simplex Virus in Cancer Therapy].
    Hao M; Huang C; Xia N
    Bing Du Xue Bao; 2016 Jul; 32(4):516-22. PubMed ID: 29996042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
    Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
    Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of oncolytic effect of recombinant Newcastle disease virus in primary and metastatic oral melanoma.
    Numpadit S; Ito C; Nakaya T; Hagiwara K
    Med Oncol; 2023 Apr; 40(5):138. PubMed ID: 37022566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncolytic Viruses for the Treatment of Metastatic Melanoma.
    Trager MH; Geskin LJ; Saenger YM
    Curr Treat Options Oncol; 2020 Mar; 21(4):26. PubMed ID: 32266483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology.
    Faries MB
    Crit Rev Oncog; 2016; 21(1-2):65-73. PubMed ID: 27481003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Awaiting a moment of truth for oncolytic viruses.
    Schmidt C
    J Natl Cancer Inst; 2013 May; 105(10):675-6. PubMed ID: 23650626
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.